About eSubmissions to FDA
1) The FDA is dedicated to improving the efficiency and effectiveness of receiving and evaluating regulatory submissions and safety assessments.
2) The FDA has issued the Final Guidance on eSubmissions (eCTD), which provides reference to the CDISC SDTM as a Study Data Specification when providing electronic submissions to FDA.
3) A regulation is being proposed that will require all regulatory submissions in electronic format and the use of CDISC SDTM. There will be an appropriate period of time allowed for compliance with this regulation.
4) The FDA is working with CDISC and HL7 on transport technologies that may ultimately replace the current SAS file method used for submissions today (see below).
5) Regardless of the transport technology, the FDA is committed to using SDTM for content and for evaluation of eSubmissions by regulatory reviewers.
CDISC Content to Message Project
FDA, in close collaboration with CDISC, is engaged in a project to develop XML messages for CDISC content that is based on the HL7 RIM (Reference Information Model). The project scope is to create four HL7 V3 messages from existing content within the CDISC standard that can ultimately be balloted in HL7.
The project involves using the BRIDG (Biomedical Research Integrated Domain Group) domain analysis model. This model (www.bridgmodel.org) is used by both CDISC and the HL7 RCRIM TC (Regulated Clinical Research Information Management Technical Committee) to harmonize standards and ensure semantic interoperability. CDISC is in charge of the content and business requirements and harmonization of the components of the CDISC standard into the BRIDG model. FDA is responsible for modeling and message development. These two streams will work in parallel with close collaboration and interaction.
A CDISC-HL7 Project Document has been produced by CDISC and FDA and presented to HL7 RCRIM. (Click Here)
For additional information, see the FDA Data Standards Council's website's CDISC Data Standards web page http://www.fda.gov/oc/datacouncil/cdisc.html
HHS—Food and Drug Administration (FDA)
Federal Register / Vol. 71, No. 237 /Monday, December 11, 2006 / The Regulatory Plan / Page 72784
PROPOSED RULE STAGE
36. ELECTRONIC SUBMISSION OF DATA FROM STUDIES EVALUATING HUMAN DRUGS AND BIOLOGICS
Priority: Other Significant. Major status under 5 USC 801 is undetermined.
Legal Authority: 21 USC 355; 21 USC 371; 42 USC 262
CFR Citation: 21 CFR 314.50; 21 CFR 601.12; 21 CFR 314.94; 21 CFR 314.96
Legal Deadline: None
Abstract: The Food and Drug Administration is proposing to amend the regulations governing the format in which clinical study data and bioequivalence data are required to be submitted for new drug applications (NDAs), biological license applications (BLAs), and abbreviated new drug applications (ANDAs). The proposal would revise our regulations to require that data submitted for NDAs, BLAs, and ANDAs, and their supplements and amendments be provided in an electronic format that
FDA can process, review, and archive. The proposal would also require the use of standardized data structure, terminology, and code sets contained in current FDA guidance (the Study Data Tabulation Model (SDTM) developed by the Clinical Data Interchange Standards Consortium) to allow for more efficient and comprehensive data review.
Department of Health and Human Services
Food and Drug Administration (FDA)
[Docket Nos. 1999D-0054, 2001D-0475, and 2003D-0364]
Guidances on Providing Regulatory Submissions in Electronic Format; Withdawal of Guidances:
SUMMARY: The Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research in announcing the withdrawal of three guidances for industry: “Providing Submissions in Electronic Format – NDAs”, “Providing Regulatory Submissions in Electronic Format—ANDAs” and “Providing Regulatory Submissions in Electronic Format: Annual Reports for NDAs and ANDAs” These guidances are being withdrawn because they are no longer consistent with more recent guidance and no longer reflect the agency’s preferred format for receiving electronic submissions.
Excerpt from body of announcement: “In October 2005, FDA issued the guidance “Providing Regulatory Submissions in Electrnic Format—Human Pharmaceutical Product Applications and Related Submissions Using the e-CTD Specifications: (the e-CTD guidance) (70 FR 60842; October 19, 2005). This guidance differs from the e-NDA and e-ANDA guidances in one significant aspet: The application table of contents is no longer submitted as a PDF file, but is submitted as an XML (extensible markup language) file.”
HHS—Food and Drug Administration (FDA)
[Docket No. 2007N—0064]
Electronic Case Report Form Submission; Notice of Pilot Project
SUMMARY: The Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research (CBER) in the Food and Drug Administration (FDA) are seeking sponsors interested in participating in a pilot project to test the submission of case report form (CRF) data provided electronically in extensible markup language (XML) base on the Operational Data Model (ODM) developed by the Clinical Data Interchange Standards Consortium (CDISC). This pilot will test the ability of a new data forma to support all review activity, which our current submission is incapable of doing. Data supplied in ODM format by sponsors during the pilot project will not replace any regulatory requirements for submitting CRFs. We anticipate that a successful pilot will allow CDER and CBER to routinely accept CRFs from studies employing electronic data capture (EDC) in ODM format in marketing applications provided in electronic format.
FDA Critical Path Opportunities Initiated During 2006
In March 2006, FDA published the second of two reports on the Critical Path to medical product development, Critical Path Opportunities Report and List. The Opportunities Report and List presented 76 specific scientific opportunities that, if undertaken, would help modernize the Critical Path sciences. The opportunities were identified through extensive outreach with patient groups, the pharmaceutical industry, academia, other federal agencies, and other health related organizations
Excerpt of Report: Streamlining Clinical Trial Data Collection
Opportunity #45
Private efforts to streamline clinical trial data collection through voluntary standardization of case report forms (CRFs) have recently been formalized under the auspices of the Clinical Data Acquisition Standards Harmonization (CDASH) Initiative. Catalyzed by the Clinical Data Interchange Standards Consortium and the Association of Contract Research Organizations, dozens of product sponsors, investigators, data managers and other stakeholders are working together to agree on a core set of data collection fields to support clinical research studies (i.e., creation of consensus CRFs and implementation guides for four "safety data/domains": adverse events, prior medications, concomitant medications, demographics and subject characteristics). FDA is providing input on issues as requested (e.g., FDA requirements). The CDASH process is open to any participant and will include a public comment process (see www.cdisc.org).
|
